The influence of commonly prescribed synthetic drugs for peptic ulcer on the pharmacokinetic fate of glycyrrhizin from Shaoyao-Gancao-tang.
The influence of synthetic drugs prescribed for peptic ulcer on the pharmacokinetic fate of glycyrrhizin (GL) from Shaoyao-Gancao-tang (SGT, a traditional Chinese formulation, Shakuyaku-Kanzo-to in Japanese) was investigated in rats. Co-administration of histamine H2-receptor antagonist (cimetidine) and anticholinergic drug (scopolamine butyl bromide) with SGT didn't influence the area under the plasma concentration-time curves (AUC) of glycyrrhetic acid (GA), an active metabolite derived from GL in SGT. The AUC of GA from SGT were significantly reduced by co-administration of synthetic drugs commonly used for peptic ulcer in a triple therapy (OAM), a combination of a proton pump inhibitor (omeprazole) and two antibiotics (amoxicillin and metronidazole). We found that the reduction of AUC in OAM treatment was due to the antibacterial effect of amoxicillin and metronidazole on intestinal bacteria in rat which lead to the decrease of GL-hydrolysis activity. The present study suggests that it may not be a proper way to use triple therapy containing antibiotics simultaneously with SGT for healing of chronic ulcers.
He
J X
JX
Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, Japan.
Akao
T
T
Nishino
T
T
Tani
T
T
D000658:Amoxicillin / Q000493:pharmacokinetics / Q000627:therapeutic use; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D019540:Area Under Curve; D002086:Butylscopolammonium Bromide / Q000494:pharmacology / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid; D002927:Cimetidine / Q000494:pharmacology / Q000627:therapeutic use; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005243:Feces / Q000737:chemistry; D006035:Glycyrrhiza; D019695:Glycyrrhizic Acid / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006868:Hydrolysis; D008297:Male; D008795:Metronidazole / Q000493:pharmacokinetics / Q000627:therapeutic use; D018727:Muscarinic Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D009853:Omeprazole / Q000493:pharmacokinetics / Q000627:therapeutic use; D029596:Paeonia; D010437:Peptic Ulcer / Q000097:blood / Q000188:drug therapy; D008517:Phytotherapy / Q000379:methods; D051381:Rats; D017208:Rats, Wistar
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D018727:Muscarinic Antagonists; C038462:shakuyaku-kanzoh-toh; D008795:Metronidazole; D002086:Butylscopolammonium Bromide; D019695:Glycyrrhizic Acid; D002927:Cimetidine; D000658:Amoxicillin; D009853:Omeprazole